Introduction:
The article discusses how Western healthcare systems are at risk of being denied access to high-quality biosimilar medicines that can reduce costs. Low and medium-income countries (LMICs) are more likely to benefit from these medicines due to lower development and manufacturing costs. The article highlights barriers in the West that deter biosimilar production and investment, while also discussing the opportunity for biosimilar innovation in the East, particularly in India.
- Incumbent biotechnology companies and inflexible regulators in the West threaten to lock out innovators from their markets and hinder the development of biosimilars.
- Innovators are turning to LMICs, such as India, where biosimilar manufacturing costs are lower and patent-protected reference products have not gained market share due to affordability issues.
- The high cost of developing biosimilars in the West, including expensive FDA and EMA regulatory requirements, consultancy fees, employee salaries, and overheads, undermines the commercial viability of biosimilar projects.
- Thin profit margins and patent thickets in the West deter investors from biosimilar projects.
- Indian developers, benefiting from lower development costs, are embracing new technology, such as QTL technology, to optimize biosimilar production and make them more affordable for LMIC markets.
Conclusion:
Western regulators and barriers, including high development costs and patent protections, pose a threat to the future of biosimilars in the West. The article highlights the opportunity for biosimilar innovation and production in the East, particularly in India, where lower costs and new technologies can enable the manufacturing of affordable biosimilar medicines. The Western healthcare systems risk being locked into expensive monopoly products and potentially face fragile supply chains as biosimilar production flourishes elsewhere. Addressing these barriers and fostering innovation in the West is crucial to ensure access to high-quality, cost-effective biosimilar medicines.
